anti-cd44 (CancerTools Org)
CancerTools Org is a verified supplier 
CancerTools Org manufactures this product 
99
Structured Review
CancerTools Org
anti-cd44
Anti Cd44, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 15474 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd44/Anti-CD44/custom%40151139%4010%2E1016%2Fj%2Eijpx%2E2026%2E100483
Average 99 stars, based on 15474 article reviews
Anti Cd44, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 15474 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti-cd44/Anti-CD44/custom%40151139%4010%2E1016%2Fj%2Eijpx%2E2026%2E100483
Average 99 stars, based on 15474 article reviews
anti-cd44 - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Ubiquitin Proteomics:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , FACS:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Flow Cytometry:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Cytometry:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Staining:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Recombinant:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Real-time Polymerase Chain Reaction:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Polymerase Chain Reaction:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Chick Chorioallantoic Membrane Assay:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Sequencing:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Light Microscopy:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Suspension:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Microscopy:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , Incubation:Article Title: Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer Article Snippet: fic antibody , EGFR , Irinotecan , 70–80 , • 1.6-fold higher intratumoral accumulation of irinotecan with BS-lipoIRI • 46.2 % reduction in tumor volume , ( Liu et al., 2022 ) . FAP. Aptm[DOX/IDO1] , , |
